CDKN2A and colon adenocarcinoma: For example, in colon adenocarcinoma (COAD), bladder urothelial carcinoma (BLCA), and liver hepatocellular carcinoma (LIHC), the high expression of CDKN2A is correlated with poor prognosis in patients.